AXSOME THERAPEUT. DL-0001 WKN: A2AA7B ISIN: US05464T1043 Kürzel: AXSM Forum: Aktien Thema: Hauptdiskussion

Nochmals ein Gailooooooooooooooooooooo!! ✌️

Endlich nach 2 Jahren im Minus.

Hab verkauft!!!

Gailooooooooooooooooo!!

Bei Acelrx hab ich nicht verkauft und trotz positiver Entscheidung 50% runter Wetten, ich verkaufe und dann geht die 100% hoch :-(

Ohje, ich weiß es im Moment auch nicht

Ab 10€ überlege ich es mir zu verkaufen

Verkaufen oder abwarten? Was macht Ihr?

Yes! Die geduldigen werden belohnt :)

7 USD sind ungefähr 6€

Kurs Stuttgart bei 4,52€!?

Thinly traded nano cap Axsome Therapeutics (NASDAQ:AXSM) is up 46% premarket on light volume in response to its announcement of positive results from a Phase 2 clinical trial, ASCEND, evaluating Fast Track-tagged AXS-05 in patients with major depressive disorder (MDD). The study met the primary endpoint of a statistically significant improvement in depression symptoms as measured by a scale called MADRS compared to bupropion. Specifically, at week 6, patients receiving AXS05, an NMDA receptor antagonist, demonstrated a 17.2-point reduction in MADRS total score versus a 12.1-point reduction for bupropion (p=0.013). At week 6, 47% of patients in the AXS-05 cohort achieved remission compared to 16% for bupropion (p-0.004). Complete data will be submitted for presentation at future medical conferences. A Phase 3 study, STRIDE-1, is in process. Management will host a conference call this morning at 8:30 am ET to discuss the results.

Wieder +40% vorbörslich NASDAQ

Boom ;-)

Axsome Therapeutics (NASDAQ:AXSM) provides year-end clinical update. Phase 3 topline results of AXS-05 in treatment-resistant depression expected in Q1 2019. Phase 3 trial of AXS-07 in acute migraine on track to start in Q1 2019. IDMC recommended Phase 2/3 of AXS-05 in Alzheimer's disease agitation continue AXS-05 treatment arm and no further randomization of bupropion treatment arm; Axsome intends to follow IDMC's recommendation. Phase 2 trial of AXS-12 for treatment of narcolepsy expected to start in January 2019, with topline results in H1 2019. Previously: Phase 2/3 study of Axsome's AXS-05 in AD-related agitation to continue; shares up 23% premarket (Dec. 10)

Thinly traded nano cap Axsome Therapeutics (NASDAQ:AXSM) is up 23% premarket on increased volume following its announcement that its Phase 2/3 clinical trial, ADVANCE-1, evaluating AXS-05 for the treatment of patients with Alzheimer's disease-related agitation will continue as planned. The independent Data Monitoring Committee recommended the continuation based on an unblinded pre-specified futility analysis. It also recommended no further randomization of subjects in the bupropion arm. AXS-05 is an orally available combination of bupropion and dextromethorphan. The role of bupropion, a norepinephrine and dopamine reuptake inhibitor and nicotinic acetylcholine receptor antagonist, is to enhance the bioavailability of dextromethorphan, an NMDA receptor antagonist, sigma-1 receptor agonist and inhibitor of the serotonin and norepinephrine transporters. Previously: Axsome therapeutics to host R&D day focused on AXS-05 and unmet needs in depression, alzheimer’s disease agitation, and nicotine dependence (March 27)